Department of Drug Evaluation & Informatics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan; Department of Clinical Data Management and Research, Clinical Research Center, National Hospital Organization Headquarters, Tokyo, Japan.
Department of Clinical Data Management and Research, Clinical Research Center, National Hospital Organization Headquarters, Tokyo, Japan; Department of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
J Clin Neurosci. 2020 Jun;76:189-194. doi: 10.1016/j.jocn.2020.04.009. Epub 2020 Apr 13.
Evidence shows that atypical antipsychotics (AAPs), a treatment of psychosis in Parkinson's disease (PD), are associated with factors reflecting the severity of the disease. Therefore, we evaluated the applicability of these factors in risk stratification for physical morbidity in PD patients requiring AAPs. We implemented a nested case-control analysis using administrative claims data derived from PD inpatients in 143 National Hospitals in Japan between April 2012 and March 2017. The analysis compared PD patients exposed to AAPs with unexposed matched controls using conditional logistic regression. The cases were then stratified by the weighted score using the partial regression coefficients of extracted factors or the number of factors that they had. Physical morbidity was evaluated using length of stay (LOS) and readmission. After comparing the cases (n = 829) with the matched controls (n = 3316), 10 factors were extracted. The cases were stratified into four level groups using the weighted score, or five level groups using the number of factors. LOS was prolonged with increasing score (49.7; 58.5; 72.7; and 83.3 days) and number of factors (52.1; 52.9; 63.9; 80.7; and 79.1 days). Readmission within 30 days increased along with increasing score (5.7; 10.2; 10.2 and 12.9%) and number of factors (5.9; 9.3; 8.9; 11.3; and 14.3%). We confirmed two stratification manners for physical morbidity in PD patients requiring AAPs. These manners would be useful for considering management plan for these patients.
证据表明,治疗帕金森病(PD)精神症状的非典型抗精神病药物(AAP)与反映疾病严重程度的因素有关。因此,我们评估了这些因素在需要 AAP 的 PD 患者身体发病率风险分层中的适用性。我们使用来自日本 143 家国立医院的 PD 住院患者的行政索赔数据,实施了一项嵌套病例对照分析。该分析使用条件逻辑回归比较了接受 AAP 治疗的 PD 患者与未暴露的匹配对照。然后,根据提取因素的偏回归系数或它们具有的因素数量,使用加权得分对病例进行分层。使用住院时间(LOS)和再入院评估身体发病率。在比较病例(n=829)和匹配对照(n=3316)后,提取了 10 个因素。使用加权得分将病例分层为四个水平组,或使用因素数量将病例分层为五个水平组。随着得分的增加,LOS 延长(49.7;58.5;72.7;和 83.3 天)和因素数量(52.1;52.9;63.9;80.7;和 79.1 天)。随着得分的增加,30 天内再入院率增加(5.7;10.2;10.2 和 12.9%)和因素数量(5.9;9.3;8.9;11.3;和 14.3%)。我们证实了两种分层方式可用于需要 AAP 的 PD 患者的身体发病率。这些方法对于考虑这些患者的管理计划将是有用的。